AbbVie Inc (ABBV) reported second quarter 2014 earnings of 82 cents per share, unchanged from the year-ago earnings but surpassing the Consensus Estimate of 76 cents. Revenues increased 5% to $4.926 billion in the second quarter of 2014, surpassing the Consensus Estimate of $4.671 billion. Results were boosted by Humira’s strong performance. Including one-time items, second quarter 2014 earnings came in at 68 cents per … Continue reading Biotech Stock in Focus: Abbvie Q2 Earnings Impress Due to Humira Sales

Shares of Puma Biotechnology, Inc (PBYI) soared significantly after the company reported positive top-line results from the phase III trial on pipeline candidate, neratinib (PB272). Puma Biotech is evaluating neratinib for the extended adjuvant treatment of breast cancer. The phase III trial, ExteNET,(n=2821) is a double blind trial, which is evaluating neratinib versus placebo after adjuvant treatment with Roche’s (RHHBY) Herceptin in women suffering from … Continue reading Biotech Stock in News: Puma Biotech Surges on Positive Results on Neratinib

There is no holding back Gilead Sciences’ (GILD – Analyst Report) hepatitis C virus (HCV) drug Sovaldi. The drug continued its exceptional performance in the second quarter of 2014, helping the company to beat the Consensus Estimate in Q2 on both revenues and earnings. The biopharmaceutical company’s second quarter adjusted earnings (including stock based compensation expenses) was of $2.32 per share. The second quarter 2014 … Continue reading Biotech Stock Top News: Gilead’s Q2 Earnings

Biogen Idec (BIIB) reported second quarter 2014 earnings per share of $3.48 (including the impact of stock-based compensation expense), way above the Consensus Estimate of $2.80 and the year-ago earnings of $2.29 per share. While oral multiple sclerosis (MS) drug, Tecfidera contributed significantly to revenues, the company also benefited from the approval of an agreement with the Italian National Medicines Agency (AIFA) relating to Tysabri … Continue reading Biotech Stock News: Biogen’s Q2 Earnings leads to a Stock Rise

Amgen Inc(AMGN) shares were up 2.5% following the company’s announcement that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a randomized, double-blind, placebo-controlled 26-week long phase III study. The study evaluated the efficacy and safety of AMG 416 in 515 chronic kidney disease (CKD) patients receiving hemodialysis and suffering from secondary hyperparathyroidism. Results showed that patients on … Continue reading Top Biotech Stock: Amgen’s AMG 416 Succeeds in Phase III